US Patent Issued to Regeneron Pharmaceuticals on May 26 for "Preferentially expressed antigen in melanoma (PRAME) T cell receptors and methods of use thereof" (Connecticut Inventors)

ALEXANDRIA, Va., May 26 -- United States Patent no. 12,636,344, issued on May 26, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Preferentially expressed antigen in melanoma (PRAME) T cell receptors and methods of use thereof" was invented by Natalie Bowerman (Stamford, Conn.) and Johanna Hansen (Greenwich, Conn.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen preferentially expressed antigen in melanoma (FRAME) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs."

The patent was filed on Jan. 22, 2021, under Application No. 17/79...